Connor, Clark & Lunn Investment Management (CC&L)’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-51,580
| Closed | -$61K | – | 1479 |
|
|
2022
Q3 | $61K | Buy |
+51,580
| New | +$61K | ﹤0.01% | 1062 |
|
|
2020
Q2 | – | Sell |
-17,685
| Closed | -$15K | – | 1208 |
|
|
2020
Q1 | $15K | Buy |
17,685
+250
| +1% | +$212 | ﹤0.01% | 993 |
|
|
2019
Q4 | $17K | Sell |
17,435
-7,809
| -31% | -$7.61K | ﹤0.01% | 907 |
|
|
2019
Q3 | $26K | Sell |
25,244
-6,925
| -22% | -$7.13K | ﹤0.01% | 942 |
|
|
2019
Q2 | $58K | Sell |
32,169
-13,063
| -29% | -$23.6K | ﹤0.01% | 964 |
|
|
2019
Q1 | $85K | Buy |
45,232
+15,908
| +54% | +$29.9K | ﹤0.01% | 874 |
|
|
2018
Q4 | $35K | Sell |
29,324
-10,200
| -26% | -$12.2K | ﹤0.01% | 925 |
|
|
2018
Q3 | $107K | Buy |
39,524
+16,800
| +74% | +$45.5K | ﹤0.01% | 885 |
|
|
2018
Q2 | $43K | Buy |
+22,724
| New | +$43K | ﹤0.01% | 1015 |
|
|
2017
Q3 | – | Sell |
-625,865
| Closed | -$983K | – | 942 |
|
|
2017
Q2 | $983K | Sell |
625,865
-42,175
| -6% | -$66.2K | 0.01% | 502 |
|
|
2017
Q1 | $2.16M | Sell |
668,040
-49,035
| -7% | -$158K | 0.01% | 373 |
|
|
2016
Q4 | $968K | Buy |
717,075
+22,200
| +3% | +$30K | 0.01% | 491 |
|
|
2016
Q3 | $1.08M | Buy |
694,875
+43,600
| +7% | +$68K | 0.01% | 459 |
|
|
2016
Q2 | $866K | Buy |
651,275
+20,000
| +3% | +$26.6K | 0.01% | 494 |
|
|
2016
Q1 | $3.33M | Buy |
631,275
+45,125
| +8% | +$238K | 0.03% | 273 |
|
|
2015
Q4 | $4.6M | Buy |
586,150
+104,775
| +22% | +$822K | 0.04% | 220 |
|
|
2015
Q3 | $4.07M | Buy |
481,375
+416,975
| +647% | +$3.52M | 0.03% | 222 |
|
|
2015
Q2 | $705K | Buy |
64,400
+15,900
| +33% | +$174K | 0.01% | 380 |
|
|
2015
Q1 | $678K | Buy |
48,500
+7,300
| +18% | +$102K | 0.01% | 358 |
|
|
2014
Q4 | $696K | Buy |
+41,200
| New | +$696K | 0.01% | 344 |
|